Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li(Beijing Tongren Hospital), Tao Zhu, Weixue Si, Rong Tang(Jiangsu Provincial Center for Disease Control and Prevention), Jin Zhong, Wenjie Tan(Sinopec (China)), Jin-Bo Gou, Fengjuan Shi(Jiangsu Provincial Center for Disease Control and Prevention), Baoying Huang(National Institute for Viral Disease Control and Prevention), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Zhuo-Pei Li(Nanjing Medical University), Xue Wang(Second Affiliated Hospital of Zhejiang University), Yin Chen(Southern Medical University), Xiaoqin Chen(North Sichuan Medical University), Xiaolong Zhao(China Pharmaceutical University), Rong Tang(Jiangsu Provincial Center for Disease Control and Prevention), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Wei Chen(Academy of Military Medical Sciences), Hongxing Pan(Jiangsu Provincial Center for Disease Control and Prevention), Xiaoyu Xu, Shipo Wu(Academy of Military Medical Sciences)
The Lancet Respiratory Medicine
May 20, 2022
Cited by 172


Related Papers